Topics

BMS, Acceleron blood cancer drug to undergo FDA expert panel review

16:17 EST 3 Dec 2019 | MedCity News

The companies said the FDA’s Oncologic Drugs Advisory Committee would review their application for Reblozyl in myelodysplastic syndrome. The drug, which won approval for a blood disorder last month, was developed under a partnership between Acceleron and Celgene, which BMS has since acquired.

Original Article: BMS, Acceleron blood cancer drug to undergo FDA expert panel review

NEXT ARTICLE

More From BioPortfolio on "BMS, Acceleron blood cancer drug to undergo FDA expert panel review"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...